染色体3p缺失驱动的VHL、HIF及表观遗传失调在透明细胞肾细胞癌中的作用
透明细胞肾细胞癌(ccRCC)是最常见的肾细胞癌亚型,转移性患者5年生存率仅10%–20%。染色体3p缺失见于>90%的散发性ccRCC,导致VHL、PBRM1、BAP1和SETD2四个抑癌基因同时单拷贝丢失,其中VHL失活驱动HIF信号过度激活和肿瘤超血管化,为VEGFR抑制剂等靶向治疗提供依据。
要点
- 染色体3p缺失是散发性ccRCC中最常见的早期遗传事件,发生率>90%。
- 3p缺失常伴随VHL(80%)、PBRM1(29%–46%)、BAP1(6%–19%)和SETD2(8%–30%)的缺失或突变。
- VHL失活导致HIF1/2α降解受阻,HIF信号过度激活和肿瘤超血管化是VEGFR抑制剂疗效的基础。
核心结论
- 3p缺失及VHL失活是ccRCC近普遍存在的主干事件,驱动HIF信号过度激活和肿瘤超血管化,是VEGFR抑制剂治疗获益的病理基础。
研究设计与样本
- 本文为综述,整合ccRCC基因组学、转录组学、蛋白质组学、代谢组学、分子机制、小鼠模型、预后/预测生物标志物及临床试验等近期进展。
主要发现
- 散发性ccRCC中染色体3p缺失发生率>90%,导致VHL、PBRM1、BAP1和SETD2四个抑癌基因同时单拷贝丢失。
- ccRCC中VHL突变频率约80%,PBRM1突变频率29%–46%,BAP1突变频率6%–19%,SETD2突变频率8%–30%。
- 3p缺失可能是散发性ccRCC的第一个遗传事件,也是VHL突变型遗传性ccRCC的第二个遗传事件。
- VHL是VCB-Cul2 E3泛素连接酶的底物识别模块,负责降解HIF1/2α;PBRM1、BAP1和SETD2是调控基因转录的表观遗传调节因子。
关键数值与推荐
- 转移性ccRCC的5年生存率为10%–20%。
- VEGFR抑制剂(索拉非尼、舒尼替尼、帕唑帕尼、阿昔替尼、贝伐珠单抗、卡博替尼、仑伐替尼)的疗效可能源于HIF1/2信号过度激活和肿瘤超血管化。
- 目前有13种药物通过7种独特治疗机制(细胞因子、VEGFR、mTORC1、cMET/AXL、FGFR、PD-1/PD-L1和CTLA-4)用于转移性肾细胞癌。
临床怎么用
- ccRCC的精准治疗需基于3p缺失/VHL失活等主干事件及表观遗传改变,合理联合和序贯不同治疗手段以优化个体化疗效。
- VEGFR抑制剂是转移性ccRCC的重要治疗选择,其获益与HIF驱动的血管生成相关。
局限性
- 本文为综述,未报告原始研究数据或系统评价方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clear cell renal cell carcinoma (ccRCC) is the most common renal cell carcinoma subtype, and metastatic ccRCC is associated with 5-year survival rates of 10% to 20%. Genetically, ccRCC originates from sequential losses of multiple tumor suppressor genes. Remarkably, chromosome 3p loss occurs in more than 90% of sporadic ccRCCs. This results in concurrent one-copy loss of four tumor suppressor genes that are also mutated individually at high frequency in ccRCC (ie, VHL, 80%; PBRM1, 29% to 46%; BAP1, 6% to 19%; and SETD2, 8% to 30%). Pathogenically, 3p loss probably represents the first genetic event that occurs in sporadic ccRCC and the second genetic event in VHL-mutated hereditary ccRCC. VHL constitutes the substrate recognition module of the VCB-Cul2 E3 ligase that degrades HIF1/2α, whereas PBRM1, BAP1, and SETD2 are epigenetic modulators that regulate gene transcription. Because 3p loss and VHL inactivation are nearly universal truncal events in ccRCC, the resulting HIF1/2 signaling overdrive and accompanied tumor hypervascularization probably underlie the therapeutic benefits observed with vascular endothelial growth factor receptor inhibitors, including sorafenib, sunitinib, pazopanib, axitinib, bevacizumab, cabozantinib, and lenvatinib. Furthermore, recent marked advances in ccRCC genomics, transcriptomics, proteomics, metabolomics, molecular mechanisms, mouse models, prognostic and predictive biomarkers, and clinical trials have rendered invaluable translational insights concerning precision kidney cancer therapeutics. With an armamentarium encompassing 13 drugs that exploit seven unique therapeutic mechanisms (ie, cytokines, vascular endothelial growth factor receptor, mTORC1, cMET/AXL, fibroblast growth factor receptor, programmed cell death-1 and programmed death-ligand 1, and cytotoxic T-cell lymphocyte associated-4) to treat metastatic renal cell carcinoma, one of the imminent clinical questions concerning care of patients with metastatic ccRCC is how a personalized treatment strategy, through rationally combining and sequencing different therapeutic modalities, can be formulated to offer the best clinical outcome for individual patients. Here, we attempt to integrate recent discoveries of immediate translational impacts and discuss future translational challenges and opportunities.
引用
- Hsieh JJ, Le VH, Oyama T, et al. Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2018. PMID: 30372397. doi:10.1200/JCO.2018.79.2549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。